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Abstract Deoxyribonuclease II (DNase II) levels in human
vary depending on whether the individual has the DNASE2*H
(high) allele or the DNASE2*L (low) allele. We examined the
promoter activity of the 5P-flanking region of each of these alleles
by transient transfection luciferase assay. DNASE2*H had 5-
fold higher promoter activity than DNASE2*L in human
hepatoma HepG2 cell. Comparison of the nucleotide sequences
of the proximal promoter regions revealed a G to A transition at
position 375; G and A residues were assigned to DNASE2*H
and *L, respectively. Since no differences were found between the
open reading frame sequences of these alleles, it is likely that the
A375G transition causes the allelic difference in the promoter
activity of the gene, underlying the genetic polymorphism.
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1. Introduction
Deoxyribonuclease II (DNase II, EC 3.1.22.1) is composed
of three non-identical subunits, which are converted from a
single-chain precursor by proteolytic processing [1,2]. Re-
cently, it has been suggested that DNase II may be responsible
for the internucleosomal DNA degradation that is character-
istic of apoptosis [3]. We have developed a sensitive and spe-
ci¢c method for measuring DNase II activity in biological
samples [4,5]. Using this assay, we showed that DNase II
activity in human urine and leukocyte lysates was bimodal
in a Japanese population [6]. We then identi¢ed two alleles
that correlate with DNase II activity, the dominant DNA-
SE2*H (high) and the recessive DNASE2*L (low) alleles,
which are situated at a single locus assigned to 19p13.2-
p13.1 [7]. The allele frequencies were determined to be 0.632
and 0.368, respectively [6]. Recently, we cloned both comple-
mentary [8] and genomic DNAs [9] encoding human DNase
II. The entire translated nucleotide sequence of DNASE2*H
was identical with that of DNASE2*L, which excluded the
possibility that the genetic polymorphism is attributable to
alterations in the primary structure of the enzyme. However,
other groups have reported that mutations or polymorphisms
in the promoter region a¡ect the promoter activity of some
genes [10^12], so we suspected that a polymorphic site(s) in
the promoter region of the DNase II gene was the primary
cause of the observed variation in its transcriptional activity,
leading to variation in the level of DNase II activity.
In this context, we examined the promoter activity of the
5P-£anking region of the genomic DNAs derived from DNA-
SE2*H and DNASE2*L, by transient transfection luciferase
assay. We identi¢ed a polymorphic site that is responsible for
allelic variation in the promoter activity.
2. Materials and methods
2.1. Biological samples and cells
Genomic DNA was isolated separately from peripheral blood leu-
kocytes collected from individuals who were homozygous for DNA-
SE2*H or DNASE2*L typed by family studies [6], using a QIAamp
Blood kit (Qiagen). The human hepatoma, HepG2 (RCB0459), and
thyroid gland cancer, TCO-1 (JCRB0239) cell lines were obtained
from the RIKEN Cell Bank and the Health Science Research Resour-
ces Bank, Japan, respectively. The cells were maintained in Dulbecco’s
modi¢ed Eagle’s medium, containing 1 mM L-glutamate, 50 U/ml
penicillin, 50 Wg/ml streptomycin, and 10% (v/v) fetal calf serum
(Life Technologies).
2.2. Ampli¢cation of genomic DNA
Based on the previously obtained sequence of the 5P-upstream re-
gion [9], we obtained fragments of the 5P-£anking region of the human
DNase II gene, by nested PCR ampli¢cation using the Genome-
Walker system (Clontech) according to the manufacturer’s instruc-
tions. The nucleotides were numbered relative to the transcription
start site (+1). DNA fragments of 577 bp, spanning from 3505 to
+72, were ampli¢ed from each genomic DNA sample, using a set of
primers that correspond to the sequences from 3505 to 3487 and
from +72 to +51 as described previously [13]: 5P-CGTGGTGTC-
GGGCGCCTG-3P (sense) and 5P-AGCTGCTATGGGGCTGAGA-
TCC-3P (antisense). The fragments ampli¢ed were subcloned directly
into a TA cloning pCR II vector (Invitrogen), and sequenced. Nucle-
otide sequences were determined by the dideoxy chain-termination
method using a Dye Terminator Cycle Sequencing FS kit (Applied
Biosystems). The sequencing run was performed on an Applied Bio-
systems Genetic Analyzer 310, and all of the DNA sequences were
con¢rmed by reading both DNA strands.
2.3. Preparation of reporter constructs
The pGL3-Basic vector (Promega) was used to make various re-
porter constructs containing fragments of the 5P-£anking region of the
human DNase II gene driving a ¢re£y luciferase gene. A DNA frag-
ment of 2301 bp (32229 to +72) was isolated from each genomic
DNA sample and then ampli¢ed using the Expanded1 High Fidelity
PCR system (Boehringer-Mannheim) and a set of primers correspond-
ing to the sequences from 32229 to 32205 and from +72 to +51:
5P-CCCACGCGTAGTGCAGTTGTTCCATCTTGGCTC-3P (sense)
and 5P-CCCCTCGAGAGCTGCTATGGGGCTGAGATCC-3P (anti-
sense), respectively. After double digestion with MluI and XhoI, the
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ampli¢ed fragment was ligated into the MluI-XhoI sites of the pGL3-
Basic vector. The reporter constructs derived from DNASE2*H and
DNASE2*L were named P1-H and P1-L, respectively. Each of the
truncated fragments from 31243, 3849, 3505, 3324, 3271, 3222,
3177, 3151, 3136, 3122 and 370 to +72 were obtained by PCR
using P1-H and P1-L, or genomic DNA of each as a template, and
then subcloned into the pGL3-Basic vector. These 11 products were
designated P2 through P12, respectively. Four internal deletion mu-
tants derived from P5, P5-v(3103/+72), P5-v(3103/312), P5-v(3103/
369) and P5-v(3144/3137), were constructed using P5-H and P5-L
constructs as templates, by the splicing by an overlap extension meth-
od [14]. Each of the reporter constructs was puri¢ed for subsequent
transfection by using the Plasmid Midi Kit (Qiagen).
2.4. Transient transfection and luciferase assay
Transient transfections were performed by the lipofection method
using Lipofectamine Plus1 reagent (Life Technologies) according to a
previously described method [15]. Each of the cell lines was cotrans-
fected with 1.0 Wg of the reporter construct and 20 ng of the pRL-TK
vector (Promega). Two days after transfection, the cells were har-
vested and lysed, and the luciferase assay in the lysate was measured.
Both the ¢re£y and Renilla luciferase activities in the lysate were
measured by using a luminometer (Lumat LB9506, EG and G Ber-
thold) with a Dual-Luciferase Reporter Assay system (Promega) ac-
cording to the manufacturer’s instructions. The vectors pGL3-Basic
and pGL3-Control (Promega) were used as promoter-less and positive
controls, respectively. All transfections were performed in triplicate,
with at least two di¡erent plasmid preparations.
3. Results
3.1. Transient expression of chimeric DNase II reporter gene
constructs
We determined the nucleotide sequence of the 5P-£anking
region of the human DNase II gene up to nucleotide position
32379 (DDBJ/EMBL/GenBank accession number
AB031422). Next we prepared 12 reporter constructs contain-
ing progressive deletions of the 2301 bp fragment ampli¢ed
from the 5P-£anking region of DNASE2*H (32229 to +72)
with the ¢re£y luciferase gene, and studied them in transient
transfection assays. Since the liver and thyroid gland show the
highest levels of DNase II activity [8], we introduced the re-
porter constructs into hepatoma (HepG2) and thyroid gland
cancer (TCO-1) cell lines, which constitutively express the
DNase II gene. In both cells the P1-H construct, containing
a 2301-bp promoter fragment, directed e¡ective expression of
the luciferase gene (Figs. 1 and 2). Stepwise deletions of this
sequence from 32229 to 3151 did not signi¢cantly a¡ect the
expression of the reporter gene. However, a drastic decrease
of luciferase activity occurred when the 3151 fragment was
reduced to 3136. Constructs P10-H to P12-H, in which fur-
ther downstream sequences were deleted, from 3151 to 3137,
3123 and 371, respectively exhibited promoter activity that
was several fold higher than that of the promoter-less expres-
sion vector pGL3-Basic. These results suggest that the region
from 32229 to 3152 is not required for basal promoter ac-
tivity, and that the regions from 3151 to 3137 and from 370
Fig. 1. Expression of luciferase activities in HepG2 cells after transi-
ent transfection. Various lengths of the 5P-£anking region of the
DNase II gene derived from DNASE2*H (solid bars) and DNA-
SE2*L (open bars) alleles were inserted upstream from the luciferase
gene in a pGL3-Basic vector. The nucleotide position numbers are
counted from the transcription start site (+1). The constructs (P1 to
P12), pGL3-Basic and pGL3-Control were cotransfected with the
pRL-TK vector into HepG2 cells by the lipofection method. The
promoter activity of each construct is expressed as the luciferase ac-
tivity of the construct relative to the Renilla luciferase activity de-
rived from pRL-TK. Values are the mean þ S.D. The positive and
promoter-less control vectors displayed relative luciferase activities
of 1890 þ 140 and 6.0 þ 0.20 in HepG2 cells, respectively.
Fig. 2. Expression of luciferase activity in TCO-1 cells after transi-
ent transfection. The details are described in the legend to Fig. 1.
The positive and promoter-less vectors displayed relative luciferase
activities of 317 þ 24.0 and 1.0 þ 0.05 in TCO-1 cells, respectively.
Fig. 3. Luciferase activities of the intra-promoter deletion mutants
of the DNase II gene. The deletion mutants of P5-H (solid bars)
and P5-L (open bars) were constructed by PCR-directed mutagene-
sis and were introduced into HepG2 cells. The promoter activity of
each construct is expressed as the luciferase activity relative to the
Renilla luciferase activity of the pRL-TK.
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to +72 together comprise a minimal promoter. Since HepG2
and TCO-1 cells provided similar results in the promoter ac-
tivity experiments for each of 12 constructs, the same cis- and
trans-acting factors are responsible for the basal promoter
activity of the gene in these cells. Next, to survey the positive
regulatory elements within this region (3151 to 3137 and
370 to +72), the e¡ect of deletions within these promoter
sequences was examined. A construct without the sequence
from 3144 to 3137, which corresponds to a putative Sp1
binding site, P5-H-v(3144/3137) exhibited only 17% of the
luciferase activity of the intact P5-H construct (Fig. 3). This
indicated that the binding of a nuclear factor to this cis-ele-
ment may be an essential event for basal promoter activity.
On the other hand, deletions of 3103 to +72 and 3103 to
312 each reduced the promoter activity to about 20% com-
pared to that of intact P5-H, whereas deletion of 3103 to 369
elevated the luciferase activity by about 3-fold compared to
the other deletion constructs (Fig. 3).
3.2. Demonstration of allelic di¡erences in DNase II gene
expression
When expressed in HepG2 and TCO-1 cells, the P1-L con-
struct derived from DNASE2*L exhibited 20% and 60%, re-
spectively, of the luciferase activity of the P1-H construct.
Furthermore, although stepwise deletion from 32229 a¡ected
the luciferase gene expression of all the constructs from these
alleles in the same manner, the constructs (P2-L to P11-L)
derived from DNASE2*L had consistently lower promoter
activity compared to the corresponding constructs (P2-H to
P11-H). These results indicate that the DNase II gene exhibits
allelic di¡erences in its promoter activity. Indeed, individuals
with the high-activity allele, DNASE2*H, have higher levels of
DNase II activity in their urine, leukocytes and semen than do
individuals who are homozygous for the low-activity allele,
DNASE2*L [4,6]. We previously reported that the observed
di¡erence in DNase II activity in biological samples is not due
to variation in the primary structure of the DNase II protein,
because there is no variation in the coding sequence [9].
Therefore, the di¡erence in the promoter activities of DNA-
SE2*H and *L, which results in the production of high and
low amounts of the gene transcript, respectively, is likely to be
the cause of the genetically determined activity levels of
DNase II.
3.3. Identi¢cation of the nucleotide substitution that generates
the allelic di¡erence in DNase II promoter activity
Comparison of the nucleotide sequences of all constructs
P4-H and P4-L through P12-H and P-12L, respectively, iden-
ti¢ed variations at two positions: di¡erent length of A-trails
at position 3336 and an A/G transition at 375 (Fig. 4). P4-H,
derived from DNASE2*H, carried (A)12 at 3336 and a G
residue at 375, whereas the P4-L, derived from DNASE2*L,
had (A)30 and an A residue. However, even constructs P5
through P11, in which the A-trail around 3336 was deleted,
exhibited allelic di¡erences in promoter activity (Figs. 1 and
2), indicating that variation in the length of the A-trail at this
position does not regulate DNase II gene transcription. On
the other hand, all of the constructs containing G residue at
375 had higher luciferase activities than their A counterparts.
Next, to ascertain whether the A/G transition at 375 in£uen-
ces DNase II promoter activity, three internal deletion mu-
tants of the P5-H and P5-L constructs, P5-v(3103/+72), P5-
v(3103/312) and P5-v(3103/369), all of which lack the re-
gion carrying the nucleotide substitution site were studied in
transition transfection assays (Fig. 3). Although the original
constructs P5-H and P5-L showed di¡erent promoter activ-
ities, as expected, all the internal deletion mutants produced
similar levels of activity irrespective of their origin. Therefore,
deletion of the nucleotide substitution site resulted in loss of
allelic speci¢city of promoter activity. On the basis of these
data, we concluded that the A/G transition at position 375
alters the promoter activity, and that the presence of a G
residue at this position brings about greater promoter activity
than that does an A residue.
Fig. 4. Nucleotide sequence of the 5P-£anking region of the DNASE2*L allele. The nucleotides are numbered relative to the transcription start
site (+1). The A/G transition site at position 375, which is responsible for the allelic di¡erence in promoter activity, is shown in boldface. An-
other variation characterized by the length of the A-trail is indicated with a dotted underline, and was identi¢ed as (A)30. In DNASE2*H this
A-trail is replaced by (A)12, as indicated over the corresponding position. Potential consensus sequences for Sp1 binding sites are underscored
with wavy lines. The cap signal and the ¢rst in-frame translation initiation codon are underlined.
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To con¢rm that there is a single nucleotide substitution at
375, DNA fragments of 577 bp, containing this site, that had
been directly ampli¢ed from DNASE2*H and *L were sub-
cloned separately. Eight independent subclones of each allele
were isolated and sequenced; all of the clones derived from
DNASE2*H had a G residue, whereas an A residue was iden-
ti¢ed in the clones from DNASE2*L.
4. Discussion
Our data suggest that a substitution of A for G at position
375 of the DNase II gene promoter may increase DNase II
gene expression, leading to higher levels of DNase II activity
underlying its genetic polymorphism. It is well documented
that a single nucleotide substitution, deletion or insertion in
a gene promoter can drastically a¡ect transcriptional activity
that is mediated by transcription factors [10,16]. In particular,
a single nucleotide substitution in the middle of a cis-acting
element can interfere with the e⁄cient binding of the corre-
sponding nuclear factors, resulting in reduced promoter activ-
ity; examples are the genes encoding low density lipoprotein
receptor [17], protein C [18], and aldehyde dehydrogenase [19].
However, the sequences around the substitution site in the
DNase II gene exhibit no similarity to any of a large variety
of transcription factor consensus sequences [20]. Changes to
the spacing and sequences between adjacent transcription fac-
tor binding sites can also a¡ect promoter activity [10,21]. In-
deed, the substitution site at 375 is located between two re-
gions responsible for the basal promoter activity of the DNase
II gene.
The 5P-£anking region of the DNase II gene exhibits several
features that are characteristic of housekeeping genes [9]. In
particular, although there are no canonical TATA or CCAAT
box consensus sequences in this area, three potential binding
sites for transcription factor Sp1 [22] are present at positions
345, 3144 and 3499. It is relatively common for at least one
Sp1 binding site to be located within the promoter of a house-
keeping gene [23] and multiple Sp1 binding sites arranged in
tandem and close to each other in a promoter region may
interact synergistically in vivo to activate transcription [17].
The results of our intra-promoter deletions suggest that both
of cis-acting elements present in the regions from 3151 to
3137 and from 368 to 312 contribute to basal promoter
activity of the DNase II gene. In fact, two Sp1 binding sites
are situated at positions 345 and 3144, within the regions of
interest. Identi¢cation of the transcriptional factors involved
in the transcriptional regulation of the human DNase II gene
is currently underway in our laboratory.
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